Adverse reactions to patent blue V dye - The New Start and Almanac experience
L. Barthelmes, A. Goyal, R.G. Newcombe, F. Mcneill, R.E. Mansel

To cite this version:
Adverse reactions to patent blue V dye - The NEW START and ALMANAC experience

Authors: L Barthelmes\textsuperscript{a}, A Goyal\textsuperscript{a}, RG Newcombe\textsuperscript{b}, F McNeill\textsuperscript{c}, RE Mansel\textsuperscript{a} on behalf of the NEW START and ALMANAC study groups.

Institution: \textsuperscript{a}Department of Surgery, School of Medicine, Cardiff University, Cardiff; \textsuperscript{b}Department of Epidemiology, Statistics and Public Health, School of Medicine, Cardiff University, Cardiff; \textsuperscript{c}Department of Surgery, Royal Marsden Hospital, London.

Address for Correspondence:

Robert E Mansel, Department of Surgery, School of Medicine, Cardiff University, Cardiff, CF14 4XN, United Kingdom

Tel: +44(0)29 2074 2749, Fax: +44(0)29 2074 2896

Email: manselre@cf.ac.uk

Category: Original article

Conflict of interest: None

Key words: anaphylaxis, allergy, breast cancer, sentinel lymph node biopsy, patent blue V, isosulfan blue
Abstract

Background

Blue dye with or without isotope has been widely used to identify the sentinel lymph node(s) in breast cancer. Patent blue V is used in the UK while its isomer isosulfan blue is used in the US. The allergic potential of isosulfan blue is well documented (1.4% adverse reactions) but that of patent blue V is less clearly defined.

Methods

In this paper we review the adverse reactions of patent blue V in 7,917 patients participating in the NEW START training programme and the ALMANAC trial. All patients underwent sentinel lymph node biopsy for breast carcinoma using patent blue V in combination with $^{99m}$Tc-albumin colloid.

Results

In total, 72 of 7,917 (0.9%) patients experienced adverse reactions: non-allergic reactions were observed in 4 (0.05%) patients, 23 (0.3%) patients had minor grade I allergic skin reactions (urticaria, blue hives, pruritis, or generalised rash) and 16 (0.2%) had grade II reactions (transient hypotension/ bronchospasm /laryngospasm). Severe Grade III reactions (severe hypotension requiring vasopressor support and/or and/or change / abandoning of planned procedure and/or HDU/ITU admission) were noted in 5 (0.06%). The type of adverse reaction was not specified in 24 (0.3%) patients. No mortality was recorded.

Conclusion

The allergic potential of patent blue V dye compares favourably with isosulfan blue however both surgeon and anaesthetist need to be alert to the risk of allergic reactions.
Introduction

Patent blue V dye has been used since the 1960’s in lymphangiography. It is a 2,5 disulfonated calcium-chelated dimer of the triphenylmethane family (CAS number 3536-49-0).\(^1\) Outside medicine it is used in textiles and as a food colourant (E 131) and potentially exposes the general population to the risk of allergic sensitisation.\(^2\) With its use in sentinel lymph node biopsy there is a renewed interest in its medical role. We reviewed our experience of its allergic potential in the large number of patients in the NEW START training programme and the ALMANAC trial. In addition, we searched the ADROITE database of the Committee of Safety of Medicines and the pharmacovigilance files of the manufacturer (Laboratoire Guerbet, Aulnay-Sous-Bois, France) and compared the rate of adverse effects of patent blue V with other dyes, namely isosulfan and methylene blue.
Patients and Methods

Before implementing sentinel lymph node biopsy (SLNB) for axillary nodal staging we investigated the procedure in a multicentre, randomised study (ALMANAC randomised controlled trial) preceded by a validation phase. We have now rolled out a UK – wide sentinel lymph node biopsy training programme (NEW START) in the UK to train breast teams and at the same time ensure patient safety.

Blue dye injection technique

In the ALMANAC validation phase and the ALMANAC randomised trial 2 ml of 2.5% aqueous solution of patent blue V diluted to 5 ml with normal saline was injected around the tumour. In the NEW START sentinel lymph node training programme undiluted 2 ml of 2.5% patent blue V dye or 2 ml of 2.5% aqueous solution of patent blue V diluted to 5 ml with normal saline was injected subdermally at the areola-skin margin of the index quadrant.

Adverse reactions

Side-effects after injection of patent blue V dye injection were recorded prospectively. The participating surgeons described the specific reaction in a free-text box. Drug treatment of the reaction (histamine antagonist, steroids or vasopressor use), admission to intensive care unit or changes of procedure were recorded. The classification of blue dye allergic reactions described by Montgomery et al. was modified and used in this study. Allergic reactions were defined as grade I (urticaria, blue hives, pruritis or generalised rash), grade II (transient hypotension/bronchospasm/laryngospasm), grade III (severe hypotension requiring vasopressor support and/or change/abandoning of planned procedure and/or HDU/ITU admission) and grade IV (cardiorespiratory arrest and/or death).
Results

Adverse reactions

9 of 839 patients in the ALMANAC validation phase, 5 of 492 patients in the ALMANAC randomised trial, and 58 of 6586 patients in the NEW START training programme were noted to have an adverse reaction to patent blue V dye. In total, 72 of 7917 (0.9 %) patients experienced adverse reactions (Table 1).

23 patients experienced minor (grade I) allergic skin reactions. Grade II allergic reactions occurred in 16 patients. 5 patients experienced severe grade III allergic reactions (Table 2).

Non-allergic reactions were observed in 4 patients. The type of adverse reaction was not specified in 24 patients. Drug treatment for grade 1 and grade 2 reactions included administration of a histamine antagonist and/or hydrocortisone. 2 of 5 patients with grade 3 reaction were admitted to HDU/ITU for observation but recovered without any sequelae. In one patient who developed severe hypotension immediately after administration of patent blue V the procedure was abandoned. The planned operative procedure had to be changed in two patients with grade 3 reactions. All patients recovered from their reactions without any long-term morbidity. There was no mortality.

Committee of the Safety of Medicines - Yellow Card Scheme

We searched the database of the Committee of the Safety of Medicines (Yellow Card Scheme in UK) for adverse reactions following the use of patent blue V. Between 7.1.1974 to 15.4.2008 there were 46 reports of 97 reactions, nearly half of them (44 / 97) due to anaphylactic immune system and skin disorders. There was one cardio-respiratory arrest, but no mortality.
Manufacturer records

Pharmacovigilance files of the manufacturer revealed 86 cases (collated worldwide, including cases reported in literature) corresponding to 158 adverse events between 1/5/2002 to 30/4/2007. As 780,705 doses were sold during the period, the reporting frequency is estimated at 11 cases per 100,000 patients and 2 adverse events for 10,000 patients (personal communication Dr. Sophie Gaillard - Guerbet).

Isosulfan blue

Several American studies have addressed the issue of allergic reactions following injection of isosulfan, an isomer of patent blue V, for sentinel lymph node biopsy in breast and melanoma patients (Table 3). Adding all studies, 1.42 % (119 / 8372) of patients were noted to have allergic reactions after injection of isosulfan blue compared with 0.86 % (68 / 7917) of patients recruited in the NEW START and ALMANAC studies (Table 3) (difference 0.56%, 95% CI 0.24 to 0.89). Severe allergic reactions with hypotension requiring treatment with vasoactive drugs (grade III allergic reaction) were noted in 0.44 % (37 / 8372) of patients after injection of isosulfan compared with 0.06 % (5 / 7917) of patients who received patent blue V (Table 3) (difference 0.38 %, 95 % CI 0.23 to 0.55).
Discussion

The combination of isotope and blue dye is the current recommended technique for sentinel node localisation in breast cancer in the UK with localisation rates of over 99%. However, blue dye is associated with a range of allergic reactions. There have been a number of case reports and single case series of anaphylactic reactions following administration of patent blue V. Its allergic potential is also reflected in reports to the Committee of Safety of Medicines and to the manufacturer. No mortality has been reported but two cardio-respiratory arrests have been attributed to patent blue V. This is the first prospective analysis of anaphylactic reactions of patent blue V dye in a large cohort. The allergic risk of patent blue V compares favourably with the published US data on isosulfan blue.

Predicted incidence of blue dye reactions in UK

Severe potentially life threatening allergic reactions are rare but the total number of adverse reactions will rise with increasing use of sentinel lymph node biopsy in the UK. NICE (National Institute of Clinical Excellence, UK) 2009 guidelines recommend that axillary staging should be performed by sentinel lymph node biopsy using a combination of isotope and blue dye. Breast cancer is the most common cancer affecting women in England and Wales, with about 44,000 new cases diagnosed each year. Approximately 25,000 - 30,000 of these patients with early stage breast cancer will undergo axillary staging by sentinel node biopsy. Based on the risk of reaction from the NEW START and ALMANAC dataset, 15 to 18 patients (0.06 %) may suffer severe grade 3 allergic reactions per annum.

It is not possible to accurately foresee anaphylaxis in a particular patient as severe allergic reactions to patent blue V have occurred in patients without any allergic
predisposition. Pre-operative antiallergic medication does not prevent anaphylactic reactions but can reduce severity.\textsuperscript{10}

Omitting patent blue V increases the false-negative rate

In an effort to minimise blue dye morbidity some centres are now performing isotope only localisation. We have some concerns with regards to this: in the ALMANAC validation phase in 10\% of patients the sentinel lymph node stained with blue dye, but did not take up \textsuperscript{99m}Tc-albumin colloid. More importantly, in approximately 4\% patients, the sentinel node that was involved with metastatic disease was identified by blue dye alone.\textsuperscript{11}

An attractive option is to use blue dye selectively in the subgroup of patients in whom a hot node is not demonstrated on the lymphoscintiscan or cannot be detected with a gamma-probe. However, there is no published data on how this approach will influence the false-negative rate. NEW START dataset analyses will be able to answer this question, however till this is done all teams should use a combined technique (isotope and blue dye) for sentinel node localisation.

\textit{Methylene blue}

Methylene blue dye due to its lower cost, lower allergic potential and lesser interference with pulse oximetry\textsuperscript{12,13} has been used as an alternative. Sentinel lymph node detection rates with methylene blue are similar to isosulfan blue\textsuperscript{14-18} despite theoretical concerns about its poor lymphatic uptake due to its lack of sulfonic acid groups essential for binding to plasma proteins and absorption into lymphatics\textsuperscript{19}. However, it is associated with fat necrosis\textsuperscript{20-22} and capsular contraction after implant surgery.\textsuperscript{23} While its allergic potential is less as reflected in fewer reports in the published literature and to the Committee of Safety of Medicines it is by no means non-existent.\textsuperscript{24,25}
Anaesthesia related anaphylaxis

Anaesthesia related anaphylaxis has been estimated at between 1 in 10,000 - 20,000. Neuromuscular blocking drugs are the commonest cause of anaesthesia related reactions. Other causes are latex hypersensitivity, antibiotics, local anaesthetics, anaesthetic induction agents, antiseptics, opioids, NSAIDs and colloids. It can be difficult to recognize the causative factor in any allergic reaction in patients undergoing blue dye guided sentinel node biopsy during general anaesthesia. However, the presence of blue hives is diagnostic of reaction to the blue dye.

Practice guidelines

We recommend that allergic risk should be documented and discussed with patients undergoing sentinel lymph node biopsy when taking consent. Patent blue V should be avoided in patients with an allergy history to foods containing food colorant E 131 or hyperallergic patients carrying an adrenaline-containing syringe for self-administration (epipen®). However, omitting blue dye may adversely affect the failed localisation and false-negative rates.

The surgeon should verbally alert the anaesthetist when patent blue V dye is administered. Since the use of patent blue V dye is on a named basis only and a licence is unlikely to be issued in future, we encourage reporting of adverse effects of patent blue V dye to the Committee of Safety of Medicines with the Yellow Card System in the UK.

Conclusion

The allergic potential of patent blue V dye compares favourably with isosulfan blue. Severe anaphylaxis is rare. However, surgical and anaesthetic teams need to be alert to the risk of allergic reactions.
Acknowledgements

We thank all patients who participated in the NEW START training programme and ALMANAC trial; other study investigators; research fellows and all the surgery, nuclear medicine, radiological, radiographic, and nursing staff at each centre.

Conflict of interest

None.
Reference List


Table 1. Adverse reactions to patent blue V dye

<table>
<thead>
<tr>
<th>Study</th>
<th>Adverse reactions to patent blue V dye</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEW START (n=6586)</td>
<td>0.9 % (58/6586)</td>
<td>0.7% - 1.1%</td>
</tr>
<tr>
<td>ALMANAC randomised phase (n=492)</td>
<td>1.0 % (5/492)</td>
<td>0.4% - 2.4%</td>
</tr>
<tr>
<td>ALMANAC validation phase (n=839)</td>
<td>1.1 % (9/839)</td>
<td>0.6% - 2.0%</td>
</tr>
<tr>
<td>Total (n=7917)</td>
<td>0.9 % (72/7917)</td>
<td>0.7% - 1.1%</td>
</tr>
</tbody>
</table>
Table 2. Side-effects of patent blue V dye

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>urticaria, blue hives, pruritis, or generalised rash</td>
<td>23 patients</td>
</tr>
<tr>
<td>II</td>
<td>transient hypotension/ bronchospasm /laryngospasm</td>
<td>16 patients</td>
</tr>
<tr>
<td>III</td>
<td>severe hypotension (requiring vasopressor support) and/or change / abandoning of planned procedure and/or HDU/ITU admission</td>
<td>5 patients</td>
</tr>
<tr>
<td>IV</td>
<td>cardio-respiratory arrest and/or death</td>
<td>-</td>
</tr>
<tr>
<td>Unspecified</td>
<td></td>
<td>24 patients</td>
</tr>
</tbody>
</table>

**Total allergic reactions**: 68

**Non-allergic reactions**

- Skin tattooing
- Bluish hue persisting for few hours

<table>
<thead>
<tr>
<th>Description</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin tattooing</td>
<td>1 patient</td>
</tr>
<tr>
<td>Bluish hue persisting for few hours</td>
<td>3 patients</td>
</tr>
</tbody>
</table>

**Total allergic + non-allergic reactions**: 72
Table 3. Allergic reactions to isosulfan blue compared to patent blue V dye

<table>
<thead>
<tr>
<th>Author</th>
<th>No. of patients</th>
<th>Agent</th>
<th>Allergic reaction</th>
<th>Grade III reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leong SP 2000(^{27})</td>
<td>406</td>
<td>Isosulfan blue</td>
<td>3 / 406 (0.7 %)</td>
<td>3 / 406 (0.7 %)</td>
</tr>
<tr>
<td>Albo D 2001(^{28})</td>
<td>639</td>
<td>Isosulfan blue</td>
<td>7 / 639 (1.1 %)</td>
<td>7 / 639 (1.1 %)</td>
</tr>
<tr>
<td>Cimmino VM 2001(^{29})</td>
<td>267</td>
<td>Isosulfan blue</td>
<td>5 / 267 (2 %)</td>
<td>2 / 267 (0.7 %)</td>
</tr>
<tr>
<td>Blessing WD 2002(^{18})</td>
<td>87</td>
<td>Isosulfan blue</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Montgomery LL 2002(^{4})</td>
<td>2392</td>
<td>Isosulfan blue</td>
<td>39 / 2392 (1.6 %)</td>
<td>9 / 2392 (0.4 %)</td>
</tr>
<tr>
<td>King TA 2004(^{30})</td>
<td>1728</td>
<td>Isosulfan blue</td>
<td>31 / 1728 (1.8 %)</td>
<td>2 / 1728 (0.1 %)</td>
</tr>
<tr>
<td>Daley MD 2004(^{31})</td>
<td>1835</td>
<td>Isosulfan blue</td>
<td>28 / 1835 (1.5 %)</td>
<td>14 / 1835 (0.75 %)</td>
</tr>
<tr>
<td>Komenaka IK 2005(^{32})</td>
<td>351</td>
<td>Isosulfan blue</td>
<td>3 / 351 (0.9 %)</td>
<td>0</td>
</tr>
<tr>
<td>Raut CP 2005(^{11})</td>
<td>667</td>
<td>Isosulfan blue</td>
<td>3 / 667 (0.4 %)</td>
<td>0</td>
</tr>
<tr>
<td>Others total</td>
<td>8372</td>
<td>Isosulfan blue</td>
<td>119 / 8372 (1.4 %)</td>
<td>37 / 8372 (0.4 %)</td>
</tr>
<tr>
<td>NEW START + ALMANAC</td>
<td>7917</td>
<td>Patent blue V</td>
<td>68 / 7917 (0.9 %)</td>
<td>5 / 7917 (0.06 %)</td>
</tr>
</tbody>
</table>